Skip to main content

Table 2 Inclusion criteria

From: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy

1. Male or female participants 6 to 25 years old at screening visit
2. History of IgE-mediated allergy to at least three foods within the following list: peanut, milk, egg, wheat, oat, soy, barley, rye, buckwheat, hazelnut, pecan, cashew, pistachio, almond, walnut and sesame
3. Participants currently following a strict avoidance of these three foods
4. Positive SPT with a largest wheal diameter ≥ 6 mm to all three foods
5. Food-specific IgE level greater than 15 kU/L for all three foods
6. Positive DBPCFC to treatment food mix with an eliciting dose ≤ 300 mg of total food protein
7. Signed informed consent and assent